WILMINGTON, Mass.--(BUSINESS WIRE)--Apr. 10, 2018--
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced that its team of oncology experts is presenting 13 scientific
posters, both independently and collaboratively with clients, and will
highlight an enhanced oncology portfolio at the American Association for
Cancer Research (AACR) Annual Meeting. The meeting is taking place from
April 14-18, 2018, at McCormick Place in Chicago, Illinois.
Showcasing Scientific Excellence
Throughout the meeting, Charles River’s experts will present the
Company’s industry-leading oncology capabilities and highlight the
latest advancements by presenting innovative applications for
CRISPR/Cas9, immuno-oncology, in vitro assays, and more.
Noteworthy posters include:
Determination of signal transduction pathway activity in
patient-derived xenograft models in comparison with clinical patient
tumor samples for a variety of human cancer types (Presented: Monday,
April 16, 8:00 a.m.-12:00 p.m.) This project, completed with
Philips Molecular Pathway Diagnostics, describes an analysis method
which identifies and quantifies activity in the cell signaling
pathways of Charles River’s patient-derived xenograft (PDX) tumor
A translational platform using primary human immune cells in
vitro, syngeneic and humanized models in vivo to support
and advance immuno-oncology drug discovery (Presented: Monday, April
16, 8:00 a.m.-12:00 p.m.) Researchers established a translational
immuno-oncology platform with the capability of progressing biologics
or small-molecule modulators of immune response from in vitro
and ex vivo through in vivo assays, including humanized
Quantitative measurement of immune-modulatory mediators within
tumors of freely moving mice utilizing in vivo microdialysis
(Presented: Tuesday, April 17, 8:00 a.m.-12:00 p.m.) Leveraging
microdialysis in tumors, researchers monitored changes in biochemical
elements within tumors to better understand cancer biology in the
development of novel therapies.
A full schedule of Charles River’s activities during AACR 2018 is
Reprints of each poster will be available in Booth #1615 during the
conference and Charles River experts will
be available for meetings to discuss how an integrated approach can
support drug discovery and development programs from hit ID to IND.
Throughout the conference, Charles River will be providing live updates
on the Eureka
Blog, including reviews of scientific sessions and input on the
research being presented.
Bioinformatic Additions to Compendium
2018, Charles River announced the launch of its new online Tumor
Model Compendium web interface. The new Compendium interface
provides oncology researchers with an easily accessible, user-friendly
resource to identify tumor models based on specific molecular and
histological properties, accompanied by selected patient information.
Ahead of AACR, Charles River will incorporate the signal transduction
pathway activity, developed with Philips
Molecular Pathway Diagnostics, as a characteristic of Charles
River’s PDX models. The resemblance of these pathways to clinical
samples will lead to better development and clinical application of
targeted drugs for personalized cancer treatment.
Select Humanization Kit
Charles River and HemaCare Corporation (OTCBB: HEMA) formed a strategic
partnership to advance human immune system research by developing a more
efficient and reliable method of working with humanized mice. Through
the partnership, HemaCare’s peripheral blood mononuclear cells (PBMCs)
are paired with Charles River’s NCG triple immunodeficient mouse. This NCG/PBMC
Select Humanization Kit is the first of
its kind in the industry and provides both the NCG mouse and vials of
prescreened human PBMCs, allowing researchers to efficiently develop
humanized mouse models on their own timeline.
“Our scientists are exploring groundbreaking applications of
innovative tools and technologies across oncology research. From
CRISPR to in vitro immuno-oncology to microdialysis, our deep
scientific bench affords us a unique opportunity to leverage learnings
from different therapeutic areas and apply them to oncology. We’re
proud to showcase our body of work at AACR this year.” –Birgit
Girshick, Corporate Executive Vice President, Discovery and Safety
Assessment, Charles River
“The continued expansion of our Tumor Model Compendium highlights the
significant role bioinformatics plays in oncology research. Scientists
require data to conduct their research efficiently and effectively.
Our Compendium puts the power of our data in their hands—eliminating
steps and driving the development process forward.” –Aidan Synnott,
Executive Director, Discovery Oncology, Charles River
About the American Association for Cancer Research
The mission of the American
Association for Cancer Research is to prevent and cure cancer
through research, education, communication, and collaboration. Through
its programs and services, the AACR fosters research in cancer and
related biomedical science; accelerates the dissemination of new
research findings among scientists and others dedicated to the conquest
of cancer; promotes science education and training; and advances the
understanding of cancer etiology, prevention, diagnosis, and treatment
throughout the world.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their research
and drug development efforts. Our dedicated employees are focused on
providing clients with exactly what they need to improve and expedite
the discovery, early-stage development and safe manufacture of new
therapies for the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180410005475/en/
Source: Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc.
E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
Amy Cianciaruso, 781-222-6168
President, Public Relations